Full Press Release Details
Receives USPTO Notice of Allowance for Patent Covering Use of CLR 131 in Multiple Myeloma
Wis., February 7, 2018 -- Cellectar Biosciences (Nasdaq: CLRB), a clinical stage biopharmaceutical company focused on the
discovery, development and commercialization of drugs for the treatment of cancer, announces that the United States Patent and
Trademark Office has issued a notice of allowance for U.S. Patent Application No. 15/095,641, entitled "Alkylphosphocholine
Analogs for Multiple Myeloma Imaging and Therapy," which covers a method of use for CLR 131, the company's lead radiotherapeutic
Phospholipid Drug Conjugate (PDC ) in multiple myeloma (MM).
Cellectar's investigational compound under development for a range of orphan designated cancers. CLR 131 utilizes the company's
patented PDC tumor targeting delivery platform to deliver the cytotoxic radioisotope iodine-131 directly to tumor cells. CLR 131
is currently being evaluated in a Phase 1 clinical trial in patients with relapse or refractory MM, as well as in a Phase 2 clinical
trial for relapsed or refractory MM and select relapsed or refractory lymphomas. The U.S. Food and Drug Administration has granted
orphan drug designation for CLR 131 in the treatment of MM.
patent allowance enhances our intellectual property estate and underscores the novelty of CLR 131 for the treatment of multiple
myeloma, a life-threatening disease with high unmet medical need," said James Caruso, chief executive officer of Cellectar
Biosciences. "Importantly, upon issuance, this patent will extend our coverage into the mid-2030s."
product candidates are built upon a patented delivery and retention platform that utilizes optimized phospholipid ether-drug conjugates
(PDCs ) to target cancer cells. The PDC platform selectively delivers diverse oncologic payloads to cancerous cells and
cancer stem cells, including hematologic cancers and solid tumors. This selective delivery allows the payloads' therapeutic
window to be modified, which may maintain or enhance drug potency while reducing the number and severity of adverse events. This
platform takes advantage of a metabolic pathway utilized by all tumor cell types in all cell cycle stages. Compared with other
targeted delivery platforms, the PDC platform's mechanism of entry does not rely upon specific cell surface epitopes or
antigens. In addition, PDCs can be conjugated to molecules in numerous ways, thereby increasing the types of molecules selectively
delivered. Cellectar believes the PDC platform holds potential for the discovery and development of the next generation of cancer-targeting
Cellectar Biosciences
is a biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer.
The company plans to develop proprietary drugs independently and through research and development (R&D) collaborations. The
core drug development strategy is to leverage our PDC platform to develop therapeutics that specifically target treatment to cancer
cells. Through R&D collaborations, the company's strategy is to generate near-term capital, supplement internal resources,
gain access to novel molecules or payloads, accelerate product candidate development and broaden our proprietary and partnered
lead PDC therapeutic, CLR 131, is in a Phase 1 clinical study in patients with relapsed or refractory (R/R) multiple myeloma (MM)
and a Phase 2 clinical study in R/R MM and a range of B-cell malignancies. In 2018 the company plans to initiate a Phase 1 study
with CLR 131 in pediatric solid tumors and lymphoma, and a second Phase 1 study in combination with external beam radiation for
head and neck cancer. The company's product pipeline also includes two preclinical PDC chemotherapeutic programs (CLR 1700
and 1900) and partnered assets include PDCs from multiple R&D collaborations.
For more information
please visit www.cellectar.com.
Statement Disclaimer
contains forward-looking statements. You can identify these statements by our use of words such as "may," "expect,"
"believe," "anticipate," "intend," "could," "estimate," "continue,"
"plans," or their negatives or cognates. These statements are only estimates and predictions and are subject to
known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements
made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery
and development involve a high degree of risk. Factors that might cause such a material difference include, among others,
uncertainties related to the ability to raise additional capital, uncertainties related to the ability to attract and retain partners
for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of
clinical trials, the FDA review process and other government regulation, our pharmaceutical collaborators' ability to successfully
develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement.
A complete description of risks and uncertainties related to our business is contained in our periodic reports filed with the
Securities and Exchange Commission including our Form 10-K for the year ended December 31, 2016. These forward-looking
statements are made only as of the date hereof, and we disclaim any obligation to update any such forward-looking statements.
LHA Investor Relations